vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and GCM Grosvenor Inc. (GCMG). Click either name above to swap in a different company.
GCM Grosvenor Inc. is the larger business by last-quarter revenue ($177.1M vs $168.4M, roughly 1.1× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 7.2%). Over the past eight quarters, GCM Grosvenor Inc.'s revenue compounded faster (27.5% CAGR vs 10.6%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
GCM Grosvenor is an American alternative asset management firm, with approximately $76 billion in assets under management and approximately 530 professionals as of 2023.
ESPR vs GCMG — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $177.1M |
| Net Profit | — | $58.2M |
| Gross Margin | — | — |
| Operating Margin | 50.6% | 30.9% |
| Net Margin | — | 32.8% |
| Revenue YoY | 143.7% | 7.2% |
| Net Profit YoY | — | 149.2% |
| EPS (diluted) | $0.32 | $0.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $177.1M | ||
| Q3 25 | $87.3M | $135.0M | ||
| Q2 25 | $82.4M | $119.7M | ||
| Q1 25 | $65.0M | $125.8M | ||
| Q4 24 | $69.1M | $165.3M | ||
| Q3 24 | $51.6M | $122.9M | ||
| Q2 24 | $73.8M | $117.0M | ||
| Q1 24 | $137.7M | $108.9M |
| Q4 25 | — | $58.2M | ||
| Q3 25 | $-31.3M | $10.5M | ||
| Q2 25 | $-12.7M | $15.4M | ||
| Q1 25 | $-40.5M | $463.0K | ||
| Q4 24 | — | $7.6M | ||
| Q3 24 | $-29.5M | $4.2M | ||
| Q2 24 | $-61.9M | $4.8M | ||
| Q1 24 | $61.0M | $2.1M |
| Q4 25 | 50.6% | 30.9% | ||
| Q3 25 | -11.4% | 32.7% | ||
| Q2 25 | 8.6% | 16.1% | ||
| Q1 25 | -34.0% | 12.2% | ||
| Q4 24 | -6.4% | 26.4% | ||
| Q3 24 | -31.0% | 20.3% | ||
| Q2 24 | 3.5% | 17.8% | ||
| Q1 24 | 52.5% | -14.7% |
| Q4 25 | — | 32.8% | ||
| Q3 25 | -35.9% | 7.8% | ||
| Q2 25 | -15.4% | 12.9% | ||
| Q1 25 | -62.2% | 0.4% | ||
| Q4 24 | — | 4.6% | ||
| Q3 24 | -57.2% | 3.4% | ||
| Q2 24 | -83.9% | 4.1% | ||
| Q1 24 | 44.3% | 2.0% |
| Q4 25 | $0.32 | $0.23 | ||
| Q3 25 | $-0.16 | $0.16 | ||
| Q2 25 | $-0.06 | $0.05 | ||
| Q1 25 | $-0.21 | $-0.02 | ||
| Q4 24 | $-0.14 | $0.09 | ||
| Q3 24 | $-0.15 | $0.03 | ||
| Q2 24 | $-0.33 | $0.04 | ||
| Q1 24 | $0.34 | $-0.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $242.1M |
| Total DebtLower is stronger | — | $428.4M |
| Stockholders' EquityBook value | $-302.0M | $27.0M |
| Total Assets | $465.9M | $813.8M |
| Debt / EquityLower = less leverage | — | 15.87× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $242.1M | ||
| Q3 25 | $92.4M | $182.7M | ||
| Q2 25 | $86.1M | $136.3M | ||
| Q1 25 | $114.6M | $94.5M | ||
| Q4 24 | $144.8M | $89.5M | ||
| Q3 24 | $144.7M | $98.4M | ||
| Q2 24 | $189.3M | $73.9M | ||
| Q1 24 | $226.6M | $41.9M |
| Q4 25 | — | $428.4M | ||
| Q3 25 | — | $429.3M | ||
| Q2 25 | — | $430.2M | ||
| Q1 25 | — | $431.1M | ||
| Q4 24 | — | $432.0M | ||
| Q3 24 | — | $432.9M | ||
| Q2 24 | — | $433.8M | ||
| Q1 24 | — | $384.0M |
| Q4 25 | $-302.0M | $27.0M | ||
| Q3 25 | $-451.4M | $-7.4M | ||
| Q2 25 | $-433.5M | $-12.3M | ||
| Q1 25 | $-426.2M | $-28.3M | ||
| Q4 24 | $-388.7M | $-27.6M | ||
| Q3 24 | $-370.2M | $-31.9M | ||
| Q2 24 | $-344.2M | $-28.5M | ||
| Q1 24 | $-294.3M | $-26.4M |
| Q4 25 | $465.9M | $813.8M | ||
| Q3 25 | $364.0M | $685.9M | ||
| Q2 25 | $347.1M | $636.9M | ||
| Q1 25 | $324.0M | $579.8M | ||
| Q4 24 | $343.8M | $612.7M | ||
| Q3 24 | $314.1M | $575.0M | ||
| Q2 24 | $352.3M | $543.9M | ||
| Q1 24 | $373.1M | $497.3M |
| Q4 25 | — | 15.87× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $183.5M |
| Free Cash FlowOCF − Capex | — | $175.0M |
| FCF MarginFCF / Revenue | — | 98.8% |
| Capex IntensityCapex / Revenue | 0.0% | 4.8% |
| Cash ConversionOCF / Net Profit | — | 3.16× |
| TTM Free Cash FlowTrailing 4 quarters | — | $326.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $183.5M | ||
| Q3 25 | $-4.3M | $79.8M | ||
| Q2 25 | $-31.4M | $42.0M | ||
| Q1 25 | $-22.6M | $33.3M | ||
| Q4 24 | $-35.0M | $148.8M | ||
| Q3 24 | $-35.3M | $69.0M | ||
| Q2 24 | $-7.2M | $17.5M | ||
| Q1 24 | $53.8M | $24.2M |
| Q4 25 | — | $175.0M | ||
| Q3 25 | — | $78.3M | ||
| Q2 25 | — | $40.8M | ||
| Q1 25 | — | $32.1M | ||
| Q4 24 | — | $132.0M | ||
| Q3 24 | $-35.5M | $62.2M | ||
| Q2 24 | $-7.3M | $12.8M | ||
| Q1 24 | $53.8M | $20.0M |
| Q4 25 | — | 98.8% | ||
| Q3 25 | — | 58.0% | ||
| Q2 25 | — | 34.1% | ||
| Q1 25 | — | 25.5% | ||
| Q4 24 | — | 79.9% | ||
| Q3 24 | -68.7% | 50.6% | ||
| Q2 24 | -9.9% | 10.9% | ||
| Q1 24 | 39.0% | 18.4% |
| Q4 25 | 0.0% | 4.8% | ||
| Q3 25 | 0.0% | 1.1% | ||
| Q2 25 | 0.0% | 1.0% | ||
| Q1 25 | 0.0% | 0.9% | ||
| Q4 24 | 0.0% | 10.1% | ||
| Q3 24 | 0.3% | 5.5% | ||
| Q2 24 | 0.1% | 4.0% | ||
| Q1 24 | 0.1% | 3.9% |
| Q4 25 | — | 3.16× | ||
| Q3 25 | — | 7.61× | ||
| Q2 25 | — | 2.72× | ||
| Q1 25 | — | 71.84× | ||
| Q4 24 | — | 19.54× | ||
| Q3 24 | — | 16.60× | ||
| Q2 24 | — | 3.64× | ||
| Q1 24 | 0.88× | 11.40× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
GCMG
| Asset Management1 | $108.6M | 61% |
| Management Service Incentive Performance Fees | $61.7M | 35% |
| Management Service Incentive Carried Interest | $5.1M | 3% |
| Service Other | $1.8M | 1% |
